KDM5B and cancer: In vitro overexpression of ZEB1 in therapy-naive cells results in downregulation of MITF, upregulation of cancer stem cell markers (e.g., NGFR and lysine demethylase 5B, JARID1B) and mesenchymal markers (e.g., VIM), and increased resistance to MAPKi.